![Sample our Physical Sciences journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110819/TOC-Subject-Sample-2021-Physical-Sciences.jpg"})
Abstract
Donepezil is an acetylcholinesterase inhibitor administered to patients who suffer from Alzheimer’s Disease (AD). We have currently developed and validated a UHPLC-DAD method for the determination of donepezil in cerebrospinal fluid. The retention time of the drug was 2.4 min and the total time of analysis was 6 min. Validation was performed in terms of linearity, selectivity, accuracy, precision, and stability. Following validation, the method was applied to clinical cerebrospinal fluid samples. The currently developed method is a reliable tool for monitoring CSF donepezil levels in patients under treatment with this drug.
Acknowledgments
The authors wish to thank ELPEN Pharmaceutical Co. Inc., Pikermi Attica, Greece, for kind donation of donepezil.